MULTIPLE MYELOMA

Daratumumab plus cyclophosphamide, bortezomib, and dexamethasone induction followed by daratumumab maintenance therapy achieved durable and deep responses in patients with newly diagnosed or relapsed multiple myeloma, regardless of transplant status.

The frequency of moderate to severe cytokine release syndrome was reduced in patients with relapsed or refractory multiple myeloma who received anakinra prophylaxis with orvacabtagene autoleucel, a BCMA-targeted CAR T-cell therapy, according to findings presented at the European Hematology Association 2021 Virtual Congress.

Updated results from the phase 1/2 CARTITUDE-1 trial showed that responses to ciltacabtagene autoleucel were deep and durable in patients with relapsed or refractory multiple myeloma. Data at a median follow-up of 18 months were presented at the 2021 European Hematology Association Congress.

The frequency of neurologic toxicities from ciltacabtagene autoleucel can be reduced with management strategies for patients with relapsed or refractory multiple myeloma treated with the chimeric antigen receptor T-cell therapy, findings from CARTITUDE-2 show.

Patients with triple-class exposed relapsed or refractory multiple myeloma demonstrated greater efficacy in terms of response and survival from treatment with ciltacabtagene autoleucel in comparison with the standard of care (SOC) in the CARTITUDE-1 trial, according to findings presented at the 2021 EHA Congress.

Daratumumab added to the standard of care with lenalidomide and dexamethasone continued to show a survival benefit over Rd alone in patients with transplant-ineligible, newly diagnosed multiple myeloma after almost 5 years of follow-up, updated results from the phase 3 MAIA trial show.

Outcomes for patients with relapsed or refractory multiple myeloma who had previously received a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 monoclonal antibody improved with the use of ciltacabtagene autoleucel as compared with conventional therapies, according to findings from propensity score–matched analyses of the CARTITUDE-1 and MAMMOTH studies.

In patients with relapsed/refractory multiple myeloma, treatment with higher doses of subcutaneous elranatamab was found to be effective, according to findings from a phase 1 clinical trial.

Sustained efficacy and durable responses was seen with Ciltacabtagene autoleucel, an investigational B-cell maturation antigen-directed CAR T-cell therapy, in heavily pretreated patients with relapsed/refractory multiple myeloma.

Updated analysis from the MonumentTAL-1 trial showed the benefits of the recommended phase II dose of talquetamab in patients with relapsed/refractory multiple myeloma.

According to updated results presented during the 2021 ASCO Annual Meeting, teclistamab administered at the recommended phase 2 dose demonstrated encouraging safety and efficacy among patients with relapsed/refractory multiple myeloma treated in a first-in-human phase 1 trial.

In newly diagnosed, transplant-eligible patients with multiple myeloma, carfilzomib consolidation with cyclophosphamide and dexamethasone conferred noninferior results compared to upfront autologous stem cell transplantation.

Efstathios Kastritis, MD, discusses the amyloidosis setting, current standards of care, and the phase 3 ANDROMEDA trial.

Results from phase 1 data looking at CART-ddBCMA show a 100% objective response rate among patients with relapsed/refractory multiple myeloma.

Allogeneic hematopoietic cell transplantation was shown to be safe when performed with a reduced-intensity conditioning regimen of bortezomib, fludarabine, and melphalan in patients with high-risk multiple myeloma

One infusion of ciltacabtagene autoleucel lead to early and deep responses in a cohort of patients previously treated for relapsed/refractory multiple myeloma, according to findings the phase 2 CARTITUDE-2 study.

Long-term follow-up data from the KarMMa trial found that treatment with the chimeric antigen receptor T-cell therapy, idecabtagene vicleucel, continues to demonstrate improved survival among heavily pretreated patients with relapsed/refractory multiple myeloma.

Treatment with daratumumab in community clinics appeared well tolerated in patients with multiple myeloma and showed similar efficacy to that observed in clinical trials.

The FDA has granted a breakthrough therapy designation to teclistamab for the treatment of relapsed or refractory multiple myeloma.

During a Targeted Oncology Case-Based Roundtable event, Sikander Ailawadhi, MD, discussed maintenance therapy for patients with multiple myeloma.

Various frontline treatments can be administered to a patient with newly-diagnosed multiple myeloma. Rafael Fonseca, MD, and a group of peers compare the available agents during a Targeted Oncology, Cased- Based Roundtable event.

David H. Vesole, MD, PhD, discussed triplet regimens used for the treatment of transplant ineligible multiple myeloma during a Targeted Oncology Case-Based Roundtable event.

David Dingli, MD, PhD, professor of Medicine at the Mayo Clinic, discussed the treatment options available for patients with transplant-eligible multiple myeloma with a group of peers during a Targeted Oncology Case-Based Roundtable event.

Melflufen flufenamide has been deemed non-inferior to pomalidomide for the treatment of relapsed/refractory (R/R) multiple myeloma.

Joseph Mikhael, MD, explained the prognostic factors for consideration when treating newly-diagnosed multiple myeloma.

Noa Biran, MD, moderated a Targeted Oncology Case-Based Roundtable event during which time experts discussed treatment rationale in multiple myeloma.

In an interview with Targeted Oncology, Bishop, discussed how CAR T cells have reshaped the treatment landscape, the future of their use, and their potential in solid tumors.

During a Targeted Oncology Case-Based Roundtable event, Rafael Fonseca, MD, discussed the case of a 72-year-old patient with multiple myeloma.

In patients with multiple myeloma, the combination of motixafortide and granulocyte colony-stimulating factor achieved a 4.9-fold increase in hematopoietic stem-cell mobilization, and prepared most patients for autologous stem cell transplant, meeting both the primary and main secondary endpoints of the GENESIS Study.

Nicolaus Kröger, MD, discusses the advantages of autologous stem cell transplant and allogeneic stem cell transplant compared with autologous tandem transplant in patients with multiple myeloma.